$AMPH
Amphastar Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000129718423000049 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $145.7M $140.0M
YoY Change 18.02% 16.33%
Cost Of Revenue $72.97M $66.18M
YoY Change 21.4% 2.54%
Gross Profit $72.74M $73.84M
YoY Change 14.81% 32.27%
Gross Profit Margin 49.92% 52.73%
Selling, General & Admin $19.00M $20.59M
YoY Change 20.74% 14.47%
% of Gross Profit 26.12% 27.89%
Research & Development $16.84M $19.82M
YoY Change -26.12% 22.14%
% of Gross Profit 23.16% 26.84%
Depreciation & Amortization $3.063M $3.399M
YoY Change 2.24% 23.96%
% of Gross Profit 4.21% 4.6%
Operating Expenses $35.84M $40.41M
YoY Change -6.98% 18.11%
Operating Profit $36.90M $33.43M
YoY Change 48.64% 54.68%
Interest Expense $3.602M $398.0K
YoY Change 807.3% 12.11%
% of Operating Profit 9.76% 1.19%
Other Income/Expense, Net -$4.088M $136.0K
YoY Change 144.5% -98.17%
Pretax Income $32.81M $33.57M
YoY Change 41.71% 15.62%
Income Tax $6.383M $6.752M
% Of Pretax Income 19.46% 20.11%
Net Earnings $26.12M $26.03M
YoY Change 50.61% 7.34%
Net Earnings / Revenue 17.93% 18.59%
Basic Earnings Per Share $0.54 $0.54
Diluted Earnings Per Share $0.49 $0.50
COMMON SHARES
Basic Shares Outstanding 48.27M 47.90M
Diluted Shares Outstanding 53.10M 51.97M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $163.1M $192.9M
YoY Change -11.04% 3.15%
Cash & Equivalents $148.6M $176.6M
Short-Term Investments $14.54M $16.28M
Other Short-Term Assets $10.76M $9.762M
YoY Change 29.09% 10.07%
Inventory $104.6M $103.6M
Prepaid Expenses
Receivables $104.7M $100.6M
Other Receivables $1.329M $731.0K
Total Short-Term Assets $384.6M $407.7M
YoY Change 1.96% 11.87%
LONG-TERM ASSETS
Property, Plant & Equipment $305.5M $243.5M
YoY Change 28.6% 0.09%
Goodwill $3.165M $3.175M
YoY Change 3.63% -2.49%
Intangibles
YoY Change
Long-Term Investments $1.462M $1.758M
YoY Change -52.3% -47.02%
Other Assets $61.14M $18.54M
YoY Change 227.23% 13.71%
Total Long-Term Assets $993.7M $366.0M
YoY Change 186.72% 4.03%
TOTAL ASSETS
Total Short-Term Assets $384.6M $407.7M
Total Long-Term Assets $993.7M $366.0M
Total Assets $1.378B $773.7M
YoY Change 90.44% 8.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $217.5M $21.98M
YoY Change 600.13% -7.82%
Accrued Expenses $3.133M $66.91M
YoY Change -95.3% -7.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $12.92M $2.168M
YoY Change 528.1% 0.42%
Total Short-Term Liabilities $251.3M $105.6M
YoY Change 142.47% -7.63%
LONG-TERM LIABILITIES
Long-Term Debt $488.3M $72.87M
YoY Change 560.99% -1.99%
Other Long-Term Liabilities $49.27M $15.18M
YoY Change 221.32% -2.06%
Total Long-Term Liabilities $537.5M $15.18M
YoY Change 3406.03% -2.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $251.3M $105.6M
Total Long-Term Liabilities $537.5M $15.18M
Total Liabilities $789.0M $225.1M
YoY Change 251.6% -4.91%
SHAREHOLDERS EQUITY
Retained Earnings $323.9M $297.8M
YoY Change 45.93% 45.54%
Common Stock $6.000K $6.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $197.4M $197.5M
YoY Change 25.78% 30.58%
Treasury Stock Shares
Shareholders Equity $589.2M $548.6M
YoY Change
Total Liabilities & Shareholders Equity $1.378B $773.7M
YoY Change 90.44% 8.02%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $26.12M $26.03M
YoY Change 50.61% 7.34%
Depreciation, Depletion And Amortization $3.063M $3.399M
YoY Change 2.24% 23.96%
Cash From Operating Activities $54.92M $40.38M
YoY Change 1851.08% -20.45%
INVESTING ACTIVITIES
Capital Expenditures $9.054M $9.477M
YoY Change -251.86% 54.37%
Acquisitions
YoY Change
Other Investing Activities -$499.5M $3.144M
YoY Change 22421.55% -205.82%
Cash From Investing Activities -$508.6M -$6.333M
YoY Change 6117.38% -30.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $968.0K
YoY Change 79.93%
Cash From Financing Activities 428.1M -13.55M
YoY Change -43169.52% -391.48%
NET CHANGE
Cash From Operating Activities 54.92M 40.38M
Cash From Investing Activities -508.6M -6.333M
Cash From Financing Activities 428.1M -13.55M
Net Change In Cash -25.55M 20.52M
YoY Change 301.76% -55.66%
FREE CASH FLOW
Cash From Operating Activities $54.92M $40.38M
Capital Expenditures $9.054M $9.477M
Free Cash Flow $45.87M $30.91M
YoY Change 422.6% -30.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Pension Expense
PensionExpense
0
CY2023Q1 us-gaap Pension Expense
PensionExpense
0
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Amphastar Pharmaceuticals, Inc.
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001297184
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Foreign Currency Contracts Liability Fair Value Disclosure
ForeignCurrencyContractsLiabilityFairValueDisclosure
0
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2535000
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36509
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0702205
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
11570 6th Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Rancho Cucamonga
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91730
CY2023Q1 dei City Area Code
CityAreaCode
909
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
980-9484
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
AMPH
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48274042
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176615000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
156098000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
235000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
235000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
16277000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
19664000
CY2023Q1 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
2200000
CY2022Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
2200000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
100638000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
88804000
CY2023Q1 us-gaap Inventory Net
InventoryNet
103647000
CY2022Q4 us-gaap Inventory Net
InventoryNet
103584000
CY2023Q1 amph Income Tax Refund And Deposits
IncomeTaxRefundAndDeposits
731000
CY2022Q4 amph Income Tax Refund And Deposits
IncomeTaxRefundAndDeposits
171000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7327000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7563000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
407670000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
378319000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
243479000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
238266000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
706000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
753000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25801000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25554000
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
1758000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
2414000
CY2023Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
37179000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
37298000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18536000
CY2023Q1 amph Payments For Deposits And Other Assets
PaymentsForDepositsAndOtherAssets
346000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20856000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
38527000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
38527000
CY2023Q1 us-gaap Assets
Assets
773656000
CY2022Q4 us-gaap Assets
Assets
741987000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
88886000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
84242000
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11590000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4571000
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2168000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3046000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2991000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3003000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
105635000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
94862000
CY2023Q1 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
7225000
CY2022Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
7225000
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
72872000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
72839000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23994000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23694000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
178000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
144000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
15175000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14565000
CY2023Q1 us-gaap Liabilities
Liabilities
225079000
CY2022Q4 us-gaap Liabilities
Liabilities
213329000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58440531
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48179238
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58110231
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48112069
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
456623000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
455077000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
297755000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
271723000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8268000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8624000
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
197539000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
189524000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
548577000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
528658000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
773656000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
741987000
CY2023Q1 us-gaap Revenues
Revenues
140022000
CY2022Q1 us-gaap Revenues
Revenues
120368000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
66182000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
64542000
CY2023Q1 us-gaap Gross Profit
GrossProfit
73840000
CY2022Q1 us-gaap Gross Profit
GrossProfit
55826000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7109000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5519000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13483000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12470000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19815000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16223000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
40407000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
34212000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
33433000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
21614000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
924000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
181000
CY2023Q1 us-gaap Interest Expense
InterestExpense
398000
CY2022Q1 us-gaap Interest Expense
InterestExpense
355000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-390000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7593000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
136000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7419000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33569000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29033000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6752000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4077000
CY2023Q1 amph Income Loss From Continuing Operations After Income Taxes
IncomeLossFromContinuingOperationsAfterIncomeTaxes
26817000
CY2022Q1 amph Income Loss From Continuing Operations After Income Taxes
IncomeLossFromContinuingOperationsAfterIncomeTaxes
24956000
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-785000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-703000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
26032000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
24253000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.54
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.50
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.50
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.47
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48000000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48138000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51970000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51979000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
26032000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
24253000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
356000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-480000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
356000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-480000
CY2022Q1 amph Payments For Deposits And Other Assets
PaymentsForDepositsAndOtherAssets
189000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10574000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5317000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14064000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26388000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
23773000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
528658000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
26032000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
356000
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
8015000
CY2023Q1 amph Stock Issued During Period Value Equity Plans
StockIssuedDuringPeriodValueEquityPlans
-4565000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6111000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
548577000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
445522000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
24253000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-480000
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1229000
CY2022Q1 amph Stock Issued During Period Value Equity Plans
StockIssuedDuringPeriodValueEquityPlans
6437000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5022000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
479525000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
26032000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
24253000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000
CY2023Q1 us-gaap Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments
GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-195000
CY2022Q1 us-gaap Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments
GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments
3013000
CY2023Q1 us-gaap Depreciation
Depreciation
6252000
CY2022Q1 us-gaap Depreciation
Depreciation
5615000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
241000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
352000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
903000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
828000
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-785000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-703000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6111000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5022000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11796000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5598000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-268000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2687000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-219000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1420000
CY2023Q1 amph Increase Decrease In Income Tax Refund Deposits And Payable
IncreaseDecreaseInIncomeTaxRefundDepositsAndPayable
-6459000
CY2022Q1 amph Increase Decrease In Income Tax Refund Deposits And Payable
IncreaseDecreaseInIncomeTaxRefundDepositsAndPayable
-3926000
CY2023Q1 amph Operating Lease Right Of Use Assets And Liabilities Net
OperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-862000
CY2022Q1 amph Operating Lease Right Of Use Assets And Liabilities Net
OperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-695000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5573000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9442000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
40382000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
50765000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9477000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6139000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6333000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9110000
CY2023Q1 amph Proceeds From Payments For Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Net Of Withholding Tax Payments
ProceedsFromPaymentsForIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsNetOfWithholdingTaxPayments
4565000
CY2022Q1 amph Proceeds From Payments For Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Net Of Withholding Tax Payments
ProceedsFromPaymentsForIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsNetOfWithholdingTaxPayments
-6437000
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
8015000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1229000
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
22000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
968000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
538000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13548000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4648000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-29000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20517000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46274000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
156333000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126588000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
176850000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
172862000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4802000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6709000
CY2023Q1 amph Noncash Operating Lease Right Of Use Asset
NoncashOperatingLeaseRightOfUseAsset
1150000
CY2022Q1 amph Noncash Operating Lease Right Of Use Asset
NoncashOperatingLeaseRightOfUseAsset
1777000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1245000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
579000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
336000
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
183000
CY2023Q1 amph Product Return Rate Percentage
ProductReturnRatePercentage
0.013
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for credit losses, fair value of financial instruments, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to its net realizable value, impairment of investments, long-lived and intangible assets and goodwill, accrual for workers’ compensation liabilities, litigation reserves, stock price volatility for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
600000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-600000
CY2022Q4 us-gaap Foreign Currency Contracts Liability Fair Value Disclosure
ForeignCurrencyContractsLiabilityFairValueDisclosure
200000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
200000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
200000
CY2023Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
2200000
CY2022Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
2200000
CY2022Q4 amph Revenue Recognition Wholesaler Chargebacks
RevenueRecognitionWholesalerChargebacks
26606000
CY2021Q4 amph Revenue Recognition Wholesaler Chargebacks
RevenueRecognitionWholesalerChargebacks
20167000
CY2023Q1 amph Revenue Recognition Wholesaler Chargebacks Provision Related To Sales In Period
RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod
69027000
CY2022Q1 amph Revenue Recognition Wholesaler Chargebacks Provision Related To Sales In Period
RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod
46779000
CY2023Q1 amph Revenue Recognition Wholesaler Chargebacks Credits Issued To Third Parties
RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties
67289000
CY2022Q1 amph Revenue Recognition Wholesaler Chargebacks Credits Issued To Third Parties
RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties
48394000
CY2023Q1 amph Revenue Recognition Wholesaler Chargebacks
RevenueRecognitionWholesalerChargebacks
28344000
CY2022Q1 amph Revenue Recognition Wholesaler Chargebacks
RevenueRecognitionWholesalerChargebacks
18552000
CY2023Q1 amph Product Return Accrual Current
ProductReturnAccrualCurrent
14100000
CY2022Q4 amph Product Return Accrual Current
ProductReturnAccrualCurrent
14900000
CY2023Q1 amph Product Return Accrual Non Current
ProductReturnAccrualNonCurrent
4700000
CY2022Q4 amph Product Return Accrual Non Current
ProductReturnAccrualNonCurrent
4600000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7419000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33569000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29033000
CY2022Q1 amph Product Return Rate Percentage
ProductReturnRatePercentage
0.016
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
26032000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
24253000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48000000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48138000
CY2023Q1 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
3970000
CY2022Q1 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
3841000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51970000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51979000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.54
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.50
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.50
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.47
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Revenues
Revenues
140022000
CY2022Q1 us-gaap Revenues
Revenues
120368000
CY2023Q1 us-gaap Gross Profit
GrossProfit
73840000
CY2022Q1 us-gaap Gross Profit
GrossProfit
55826000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
40407000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
34212000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
33433000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
21614000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
136000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3399000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2742000
CY2023Q1 us-gaap Revenues
Revenues
140022000
CY2022Q1 us-gaap Revenues
Revenues
120368000
CY2023Q1 us-gaap Noncurrent Assets
NoncurrentAssets
269986000
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
264573000
CY2023Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
19979000
CY2023Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
29000
CY2023Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
19950000
CY2022Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
23515000
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
62000
CY2022Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
23453000
CY2023Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11681000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6902000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4779000
CY2023Q1 amph Indefinite Lived Intangible Assets Including Goodwill Gross
IndefiniteLivedIntangibleAssetsIncludingGoodwillGross
32400000
CY2023Q1 amph Indefinite Lived Intangible Assets Including Goodwill Net
IndefiniteLivedIntangibleAssetsIncludingGoodwillNet
32400000
CY2023Q1 amph Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
44081000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6902000
CY2023Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
37179000
CY2022 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11488000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6541000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4947000
CY2022Q4 amph Indefinite Lived Intangible Assets Including Goodwill Gross
IndefiniteLivedIntangibleAssetsIncludingGoodwillGross
32351000
CY2022Q4 amph Indefinite Lived Intangible Assets Including Goodwill Net
IndefiniteLivedIntangibleAssetsIncludingGoodwillNet
32351000
CY2022Q4 amph Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
43839000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6541000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
37298000
CY2022Q4 us-gaap Goodwill
Goodwill
3126000
CY2021Q4 us-gaap Goodwill
Goodwill
3313000
CY2023Q1 us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
49000
CY2022 us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
-187000
CY2023Q1 us-gaap Goodwill
Goodwill
3175000
CY2022Q4 us-gaap Goodwill
Goodwill
3126000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
88886000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
84242000
CY2023Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
47919000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
47607000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
30873000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
37090000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
24855000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
18887000
CY2023Q1 us-gaap Inventory Net
InventoryNet
103647000
CY2022Q4 us-gaap Inventory Net
InventoryNet
103584000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
1900000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
8000000.0
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
739000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
790000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
470063000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
458296000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
226584000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
220030000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
243479000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
238266000
CY2023Q1 amph Accrued Customer Fees And Rebates
AccruedCustomerFeesAndRebates
17030000
CY2022Q4 amph Accrued Customer Fees And Rebates
AccruedCustomerFeesAndRebates
14198000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23940000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22847000
CY2023Q1 amph Product Return Accrual Current
ProductReturnAccrualCurrent
14148000
CY2022Q4 amph Product Return Accrual Current
ProductReturnAccrualCurrent
14867000
CY2023Q1 amph Reserve For Net Loss On Firm Purchase Commitments
ReserveForNetLossOnFirmPurchaseCommitments
3075000
CY2022Q4 amph Reserve For Net Loss On Firm Purchase Commitments
ReserveForNetLossOnFirmPurchaseCommitments
2686000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8714000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9143000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
66907000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
63741000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
21979000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
20501000
CY2023Q1 us-gaap Contractual Obligation
ContractualObligation
76470000
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
77432000
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2168000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3046000
CY2023Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1430000
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1547000
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
72872000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
72839000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33569000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29033000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6752000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4077000
CY2023Q1 amph Income Loss From Continuing Operations After Income Taxes
IncomeLossFromContinuingOperationsAfterIncomeTaxes
26817000
CY2022Q1 amph Income Loss From Continuing Operations After Income Taxes
IncomeLossFromContinuingOperationsAfterIncomeTaxes
24956000
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.201
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.140
CY2023Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
235000000.0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.415
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.411
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.022
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7929150
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.66
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700601
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.13
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
102024
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.61
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1601
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
31.21
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8526126
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.15
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
156491000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6376523
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.25
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
135510000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8270035
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.83
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y10D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
154400000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.67
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.06
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2341000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12200000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1388000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12450000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
7584000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6987000
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2378453
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
9.48
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700601
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.67
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
927850
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
8.17
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
1601
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
13.96
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2149603
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
12.39
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6111000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5022000
CY2023Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2023Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2023Q1 us-gaap Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
0.0375
CY2023Q1 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
2300000
CY2022Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
2200000
CY2023Q1 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
4900000
CY2022Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
4500000
CY2023Q1 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
5000000.0
CY2022Q4 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
4600000

Files In Submission

Name View Source Status
amph-20230331_cal.xml Edgar Link unprocessable
0001297184-23-000049-index-headers.html Edgar Link pending
0001297184-23-000049-index.html Edgar Link pending
0001297184-23-000049.txt Edgar Link pending
0001297184-23-000049-xbrl.zip Edgar Link pending
amph-20230331.xsd Edgar Link pending
amph-20230331x10q.htm Edgar Link pending
amph-20230331xex10d1.htm Edgar Link pending
amph-20230331xex31d1.htm Edgar Link pending
amph-20230331xex31d2.htm Edgar Link pending
amph-20230331xex32d1.htm Edgar Link pending
amph-20230331x10q_htm.xml Edgar Link completed
amph-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
amph-20230331_def.xml Edgar Link unprocessable
amph-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amph-20230331_pre.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending